Meningioma in patients exposed to progestin drugs: results from a real-life screening program - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Journal of Neuro-Oncology Année : 2022

Meningioma in patients exposed to progestin drugs: results from a real-life screening program

Résumé

Purpose: To report the results of systematic meningioma screening program implemented by French authorities in patients exposed to progestin therapies (cyproterone (CPA), nomegestrol (NA), and chlormadinone (CMA) acetate). Methods: We conducted a prospective monocentric study on patients who, between September 2018 and April 2021, underwent standardized MRI (injection of gadolinium, then a T2 axial FLAIR and a 3D-T1 gradient-echo sequence) for meningioma screening. Results: Of the 210 included patients, 15 (7.1%) had at least one meningioma; seven (7/15, 47%) had multiple meningiomas. Meningiomas were more frequent in older patients and after exposure to CPA (13/103, 13%) compared to NA (1/22, 4%) or CMA (1/85, 1%; P=0.005). After CPA exposure, meningiomas were associated with longer treatment duration (median=20 vs 7 years, P=0.001) and higher cumulative dose (median=91 g vs. 62 g, P=0.014). Similarly, their multiplicity was associated with higher dose of CPA (median=244 g vs 61 g, P=0.027). Most meningiomas were ≤1 cm 3 (44/58, 76%) and were convexity meningiomas (36/58, 62%). At diagnosis, patients were non-symptomatic, and all were managed conservatively. Among 14 patients with meningioma who stopped progestin exposure, meningioma burden decreased in 11 (79%) cases with no case of progression during MR follow-up. Conclusion: Systematic MR screening in progestin-exposed patients uncovers small and multiple meningiomas, which can be managed conservatively, decreasing in size after progestin discontinuation. The high rate of meningiomas after CPA exposure reinforces the need for systematic screening. For NA and CMA, further studies are needed to identify patients most likely to benefit from screening.
Fichier principal
Vignette du fichier
Samoyeau et al (Oppenheim).pdf (2.14 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-03854767 , version 1 (16-11-2022)

Identifiants

Citer

Thomas Samoyeau, Corentin Provost, Alexandre Roux, Laurence Legrand, Edouard Dezamis, et al.. Meningioma in patients exposed to progestin drugs: results from a real-life screening program. Journal of Neuro-Oncology, 2022, 160 (1), pp.127 - 136. ⟨10.1007/s11060-022-04124-2⟩. ⟨inserm-03854767⟩
57 Consultations
49 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More